Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review

[1]  P. Stute,et al.  Care reality of menopausal women in Germany: healthcare research using quantitative (SHI claims data) and qualitative (survey) data collection , 2022, Archives of Gynecology and Obstetrics.

[2]  P. Stute,et al.  Assessment of the climacteric syndrome: a narrative review , 2021, Archives of Gynecology and Obstetrics.

[3]  Ying Feng,et al.  What is behind the fear of cancer during menopausal hormone therapy in China? , 2021, Archives of Gynecology and Obstetrics.

[4]  V. Vaccarino,et al.  Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[5]  P. Benedetti Panici,et al.  Does Hormone Replacement Therapy Impact the Prognosis in Endometrial Cancer Survivors? A Systematic Review , 2020, Oncology.

[6]  A. Cagnacci,et al.  The Controversial History of Hormone Replacement Therapy , 2019, Medicina.

[7]  V. Beral,et al.  Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence , 2019, The Lancet.

[8]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[9]  J. Hippisley-Cox,et al.  Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases , 2019, British Medical Journal.

[10]  Arun S. Hendi,et al.  Recent trends in life expectancy across high income countries: retrospective observational study , 2018, British Medical Journal.

[11]  P. Spritzer,et al.  Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. , 2018, Thrombosis research.

[12]  Guangquan Li,et al.  Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble , 2017, The Lancet.

[13]  C. Farquhar,et al.  Long-term hormone therapy for perimenopausal and postmenopausal women. , 2017, The Cochrane database of systematic reviews.

[14]  M. Rees,et al.  Revised Global Consensus Statement on Menopausal Hormone Therapy , 2016, Climacteric : the journal of the International Menopause Society.

[15]  I. Lambrinoudaki,et al.  Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). , 2016, Maturitas.

[16]  M. Rees,et al.  Revised global consensus statement on menopausal hormone therapy. , 2016, Maturitas.

[17]  L. Kocoska-Maras,et al.  Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration , 2016, Menopause.

[18]  J. Simon,et al.  Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy , 2016, Menopause.

[19]  N. Panay,et al.  2016 IMS Recommendations on women’s midlife health and menopause hormone therapy , 2016, Climacteric : the journal of the International Menopause Society.

[20]  Isabelle Boutron,et al.  A revised tool for assessing risk of bias in randomized trials , 2016 .

[21]  V. Montori,et al.  Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis. , 2015, The Journal of clinical endocrinology and metabolism.

[22]  J. Manson,et al.  Management of Menopausal Symptoms. , 2015, Obstetrics and gynecology.

[23]  Ji Soo Lee,et al.  Effects of Hormone Therapy on Serum Lipid Levels in Postmenopausal Korean Women , 2015, Journal of menopausal medicine.

[24]  M. Russu,et al.  Endometrial histology and safety in healthy permenopausal and early postmenopausal women after an oral fourphasic contraceptive. Results after 2 years monitoring , 2015 .

[25]  Richard D Riley,et al.  Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement , 2015 .

[26]  R. Santen.  Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels , 2015, Climacteric : the journal of the International Menopause Society.

[27]  Ji Soo Lee,et al.  Effect of Transdermal Estrogen Therapy on Bone Mineral Density in Postmenopausal Korean Women , 2014, Journal of menopausal medicine.

[28]  C. Castelo-Branco,et al.  Clinical efficacy of estradiol transdermal system in the treatment of hot flashes in postmenopausal women , 2014 .

[29]  Mark Loeb,et al.  Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments , 2014, BMC Medical Research Methodology.

[30]  C. Gracia.  Practice Bulletin No. 141: Management of Menopausal Symptoms , 2014, Obstetrics and gynecology.

[31]  V. Beral,et al.  Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study , 2012, Journal of thrombosis and haemostasis : JTH.

[32]  Dwain E. Woode,et al.  American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause: executive summary of recommendations. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[33]  Rowena J Dolor,et al.  Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. , 2011, Journal of the American College of Cardiology.

[34]  W. Mack,et al.  A “window of opportunity:” The reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent , 2011, Brain Research.

[35]  S. Suissa,et al.  Hormone replacement therapy and the risk of venous thromboembolism: a population‐based study , 2010, Journal of thrombosis and haemostasis : JTH.

[36]  F. Clavel-Chapelon,et al.  Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism: Results From the E3N Cohort Study , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[37]  W. Rocca,et al.  Premature menopause or early menopause: long-term health consequences. , 2010, Maturitas.

[38]  N. Carroll.  A review of transdermal nonpatch estrogen therapy for the management of menopausal symptoms. , 2010, Journal of women's health.

[39]  F. Clavel-Chapelon,et al.  Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Générale de l’Education Nationale (E3N) cohort , 2009, Diabetologia.

[40]  E. Pukkala,et al.  Breast Cancer Risk in Postmenopausal Women Using Estradiol–Progestogen Therapy , 2009, Obstetrics and gynecology.

[41]  Daniel J. Thompson,et al.  Transdermal hormone therapy in postmenopausal women: A review of metabolic effects and drug delivery technologies , 2008, Drug design, development and therapy.

[42]  R. Jacobsen,et al.  Hormone Therapy and Risk of Myocardial Infarction : A National Register Study , 2009 .

[43]  R. Jacobsen,et al.  Hormone therapy and risk of myocardial infarction: a national register study. , 2008, European heart journal.

[44]  P. Kenemans,et al.  Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. , 2008, Fertility and sterility.

[45]  S. Suissa,et al.  Hormone replacement therapy use and variations in the risk of breast cancer , 2007, BJOG : an international journal of obstetrics and gynaecology.

[46]  F. Clavel-Chapelon,et al.  Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study , 2008 .

[47]  C. la Vecchia,et al.  Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  F. Drobniewski,et al.  Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women : systematic review and meta-analysis , 2008 .

[49]  J. Heikkinen,et al.  One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. , 2007, Maturitas.

[50]  J. Berek,et al.  Prognostic Factors for Uterine Cancer in Reproductive-Aged Women , 2007, Obstetrics and gynecology.

[51]  F. Clavel-Chapelon,et al.  Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study , 2007, Breast Cancer Research and Treatment.

[52]  E. Oger,et al.  Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study , 2007, Circulation.

[53]  R. Lobo,et al.  A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. , 2006, Fertility and sterility.

[54]  G. Rosano,et al.  Hormone Replacement Therapy and Cardioprotection , 2006, Annals of the New York Academy of Sciences.

[55]  E. Pukkala,et al.  Breast Cancer Risk in Postmenopausal Women Using Estrogen-Only Therapy , 2006, Obstetrics and gynecology.

[56]  I. Lambrinoudaki,et al.  Differential Effect of Hormone Therapy and Tibolone on Lipids, Lipoproteins, and the Atherogenic Index of Plasma , 2006, Journal of cardiovascular pharmacology.

[57]  R. Farmer,et al.  Myocardial infarction risk and hormone replacement: differences between products. , 2006, Maturitas.

[58]  E. Oger,et al.  Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration , 2005, Circulation.

[59]  X. Bonfill,et al.  Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. , 2005, The Cochrane database of systematic reviews.

[60]  F. Clavel-Chapelon,et al.  Breast cancer risk in relation to different types of hormone replacement therapy in the E3N‐EPIC cohort , 2005, International journal of cancer.

[61]  J. Lidfeldt,et al.  Combined hormone therapy in postmenopausal women with features of metabolic syndrome. Results from a population-based study of Swedish women: Women’s Health in the Lund Area study , 2004, Menopause.

[62]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[63]  C. Chilvers,et al.  Post menopausal hormone replacement therapy and risk of acute myocardial infarction--a case control study of women in the East Midlands, UK. , 2003, European heart journal.

[64]  P. Crosignani.  Breast cancer and hormone-replacement therapy in the Million Women Study. , 2003, Maturitas.

[65]  Mark Garton,et al.  Breast cancer and hormone-replacement therapy: the Million Women Study , 2003, The Lancet.

[66]  A. LaCroix,et al.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.

[67]  Cristiana Maria Rocha Fidalgo dos Reis,et al.  Body composition, visceral fat distribution and fat oxidation in postmenopausal women using oral or transdermal oestrogen. , 2003, Maturitas.

[68]  A. Yazgan,et al.  Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women. , 2003, Fertility and sterility.

[69]  Valerie Beral,et al.  Breast cancer and hormone-replacement therapy in the Million Women Study , 2003, The Lancet.

[70]  E. Oger,et al.  Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk , 2003, The Lancet.

[71]  J. Foidart,et al.  Comparaison de l’évolution des marqueurs biologiques du remodelage osseux après six mois de traitement hormonal substitutif par 17β–estradiol cutané ou estrogènes sulfoconjugués équins et acétate de nomégestrol , 2003 .

[72]  J. Hippisley-Cox,et al.  A case-control study on the effect of hormone replacement therapy on ischaemic heart disease. , 2003, The British journal of general practice : the journal of the Royal College of General Practitioners.

[73]  J. Foidart,et al.  [Comparison of changes in biochemical markers of bone turnover after 6 months of hormone replacement therapy with either transdermal 17 beta-estradiol or equine conjugated estrogen plus nomegestrol acetate]. , 2003, Gynécologie Obstétrique & Fertilité.

[74]  A. Wakatsuki,et al.  Different Effects of Oral Conjugated Equine Estrogen and Transdermal Estrogen Replacement Therapy on Size and Oxidative Susceptibility of Low-Density Lipoprotein Particles in Postmenopausal Women , 2002, Circulation.

[75]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[76]  M. Çetinkaya,et al.  Comparison of the effects of transdermal estrogen, oral estrogen, and oral estrogen-progestogen therapy on bone mineral density in postmenopausal women , 2002, Journal of Bone and Mineral Metabolism.

[77]  M. C. Terek,et al.  Sequential combined transdermal and oral postmenopausal hormone replacement therapies: effects on bleeding patterns and endometrial histology , 2001, Archives of Gynecology and Obstetrics.

[78]  M. Savolainen,et al.  Effects of peroral and transdermal oestrogen replacement therapy on glucose and insulin metabolism , 2001, Clinical endocrinology.

[79]  B. Karakoç,et al.  Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance , 2001, Climacteric : the journal of the International Menopause Society.

[80]  L. García-Rodríguez,et al.  Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. , 2000, Circulation.

[81]  M. Whitehead,et al.  A randomised comparison of the effects of oral versus transdermal 17β‐oestradiol, each combined with sequential oral norethisterone acetate, on serum lipoprotein levels , 1999, British journal of obstetrics and gynaecology.

[82]  J. Torhorst,et al.  Continuous, combined hormone replacement: randomized comparison of transdermal and oral preparations. , 1999, Obstetrics and gynecology.

[83]  A. O’Sullivan,et al.  The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. , 1998, The Journal of clinical investigation.

[84]  J. Castellsagué,et al.  Hormone replacement therapy and risk of venous thromboembolism: population based case-control study , 1997, BMJ.

[85]  G. Anelli,et al.  Effect of oral and transdermal hormone replacement therapy on lipid profile and Lp(a) level in menopausal women with hypercholesterolemia. , 1996, International journal of fertility and menopausal studies.

[86]  J. Carson,et al.  Risk of venous thromboembolism in users of hormone replacement therapy , 1996, The Lancet.

[87]  R. Marcus,et al.  The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. , 1995, The Journal of clinical endocrinology and metabolism.

[88]  S. Palacios,et al.  Effects of percutaneous oestradiol versus oral oestrogens on bone density. , 1994, Maturitas.

[89]  M. Whitehead,et al.  Long-Term Effects of Oral and Transdermal Hormone Replacement Therapies on Serum Lipid and Lipoprotein Concentrations , 1994, Obstetrics and gynecology.

[90]  S. Adami,et al.  Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. , 1993, Maturitas.

[91]  I. Godsland,et al.  Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. , 1993, Metabolism: clinical and experimental.

[92]  K. Ho,et al.  Impact of short‐term estrogen administration on growth hormone secretion and action: Distinct route‐dependent effects on connective and bone tissue metabolism , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[93]  K. Matthews,et al.  Weight gain at the time of menopause. , 1991, Archives of internal medicine.

[94]  K. Ho,et al.  Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. , 1991, The Journal of clinical endocrinology and metabolism.

[95]  M. Whitehead,et al.  Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women , 1990, The Lancet.

[96]  B. Dawson-Hughes,et al.  Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. , 1986, The Journal of clinical endocrinology and metabolism.